273 related articles for article (PubMed ID: 29405977)
1. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.
Maji S; Panda S; Samal SK; Shriwas O; Rath R; Pellecchia M; Emdad L; Das SK; Fisher PB; Dash R
Adv Cancer Res; 2018; 137():37-75. PubMed ID: 29405977
[TBL] [Abstract][Full Text] [Related]
2. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
4. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
5. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
6. Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2004 Oct; 25(10):1867-77. PubMed ID: 15205359
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
8. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
[TBL] [Abstract][Full Text] [Related]
9. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
10. FKBP38-Bcl-2 interaction: a novel link to chemoresistance.
Choi BH; Yoon HS
Curr Opin Pharmacol; 2011 Aug; 11(4):354-9. PubMed ID: 21571591
[TBL] [Abstract][Full Text] [Related]
11. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug resistance by enhancing apoptosis of tumor cells.
Giménez-Bonafé P; Tortosa A; Pérez-Tomás R
Curr Cancer Drug Targets; 2009 May; 9(3):320-40. PubMed ID: 19442052
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of antiapoptotic BCL-2 proteins in cancer.
Timucin AC; Basaga H; Kutuk O
Med Res Rev; 2019 Jan; 39(1):146-175. PubMed ID: 29846950
[TBL] [Abstract][Full Text] [Related]
15. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.
Gabellini C; Trisciuoglio D; Del Bufalo D
Carcinogenesis; 2017 Jun; 38(6):579-587. PubMed ID: 28203756
[TBL] [Abstract][Full Text] [Related]
16. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy.
Heere-Ress E; Thallinger C; Lucas T; Schlagbauer-Wadl H; Wacheck V; Monia BP; Wolff K; Pehamberger H; Jansen B
Int J Cancer; 2002 May; 99(1):29-34. PubMed ID: 11948488
[TBL] [Abstract][Full Text] [Related]
17. Targeting Bcl-2 for cancer therapy.
Zhang L; Lu Z; Zhao X
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188569. PubMed ID: 34015412
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 inhibitors: emerging drugs in cancer therapy.
Bodur C; Basaga H
Curr Med Chem; 2012; 19(12):1804-20. PubMed ID: 22414090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
